‘Protective shield’ for beta-cells suggests new option to treat diabetes – Medical Xpress

June 21, 2017 Credit: Medical University of Vienna

The islets of Langerhans in the human pancreas produce and release insulin to regulate blood glucose levels. Insulin, which is specifically produced in b-cells, serves to prompt cells to take up glucose circulating in blood. Thus, insulin release lowers the level of glucose in blood. In diabetes, this cycle is disrupted by the premature death of b-cells. Working with an international team of researchers, Katarzyna Malenczyk from the Department of Molecular Neurosciences at MedUni Vienna's Center for Brain Research showed in the study published in the EMBO Journal today that the loss of a key protein, secretagogin, triggers the death of b-cells and, conversely, that these cells can be protected by increasing the amount of this protein in those suffering from diabetes.

"Although researchers have been trying for decades to find effective means of protecting b-cells in diabetes, we still haven't found curative therapies. Understanding the mechanism that could lead to the development of a medication is therefore of enormous value," says Dr. Malenczyk, lead author of a new study. "We were able to show in animal models and also in b-cells from diabetic donors that, in disease conditions the level of secretagogin is significantly reduced, suggesting a direct correlation between this protein and the severity of the disease," explains Tibor Harkany, Head of the Department of Molecular Neurosciences of MedUni Vienna's Center for Brain Research. "If we find molecular tools to keep b-cells active, we could also ensure their survival."

So far, research on the protein secretagogin has been limited. Yet, Dr. Malencyzk and an international team led by the Department of Molecular Neurosciences at the Center for Brain Research have now discovered that the presence of this protein is critical for bcells to remain healthy, and therefore represents a target for the development of an effective treatment for diabetes whether prevention or therapy at clinical onset is considered.

Mechanism explained

The most important outcome of this study is to show that secretagogin regulates whether and how b-cells shed all those proteins that are no longer required or useful to maintain their physiological integrity and functions. Professor Harkany remarks: "If secretagogin is turned off, toxic proteins as waste products can rapidly accumulate in bcells and this inevitably leads to their death." And so, if levels of secretagogin in b-cells could be boosted in diabetes to remain near-physiological, this would offer an attractive avenue of their self-protection.

Secretagogin a Viennese discovery

The protein secretagogin was first identified by Ludwig Wagner (Department of Medicine III), who is also co-author of the current paper, in Vienna in 2000. Seventeen years later, the present study demonstrates the exact role of this protein. Professor Wagner says: "It is nail-biting to see that our continued study of this single protein has reached a stage where the molecular understanding of its function can realize the development of new treatment options."

Fuelling secretagogin levels

But how can cellular levels of this protein be boosted in diabetes? Dr. Malenczyk and the international research team around her showed that the protein can be retained in diabetes and its activity increased by stimulating TRPV ion channels. TRPV1 is a transmembrane protein that besides the nervous system is also expressed in pancreatic beta-cells. If this receptor is stimulated, more secretagogin is being produces in b-cells. TRPV1 is easiest stimulated by capsaicin, an alkaloid that occurs in various types of bell and chilli pepper. Capsaicin binds directly to TRPV1 ion channels and by stimulating them has a profound effect on b-cell biology. Dr. Malenczyk notes: "In a first step, our discovery could be an efficient treatment for diabetes but, of course, this requires follow-up studies in human sufferers. We are cautious to suggest that that diabetics could improve their diets by consuming more peppers or chillies. TRPV1 is a promising target for potential drugs, because, in diabetes, it continues to be found with its levels largely unaltered in b-cells.

Explore further: 'Trigger' for stress processes discovered in the brain

More information: A TRPV1-to-secretagogin regulatory axis controls pancreatic beta-cell survival by modulating protein turnover. Katarzyna Malenczyk, Fatima Girach, Edit Szodorai, Petter Storm, sa Segerstolpe, Giuseppe Tortoriello, Robert Schnell, Jan Mulder, Roman A. Romanov, Erzsbet Bork, Fabiana Piscitelli, Vincenzo Di Marzo, Gbor Szab, Rickard Sandberg, Stefan Kubicek, Gert Lubec, Tomas Hkfelt, Ludwig Wagner, Leif Groop and Tibor Harkany, EMBO Journal, 2017. DOI: 10.15252/emboj.201695347

At the Center for Brain Research at the MedUni Vienna an important factor for stress has been identified in collaboration with the Karolinska Institutet in Stockholm (Sweden). This is the protein secretagogin that plays an ...

Pancreatic beta cells help maintain normal blood glucose levels by producing the hormone insulinthe master regulator of energy (glucose). Impairment and the loss of beta cells interrupts insulin production, leading to ...

Type-1 diabetes occurs when immune cells attack the pancreas. EPFL scientists have now discovered what may trigger this attack, opening new directions for treatments.

Diabetes continues to be a global health problem, with the number of cases projected to rise from 285 million in 2010 to nearly 400 million by the year 2030. Diabetes is the fourth leading cause of death worldwide.

Research led by a Johns Hopkins University biologist demonstrates the workings of a biochemical pathway that helps control glucose in the bloodstream, a development that could potentially lead to treatments for diabetes.

The significant role of beta cell 'hubs' in the pancreas has been demonstrated for the first time, suggesting that diabetes may due to the failure of a privileged few cells, rather than the behaviour of all cells.

Heart disease is a leading cause of death worldwide and exacerbated by type 2 diabetes, yet diabetes treatment regimens tend to focus primarily on blood sugar maintenance. This common approach to type 2 diabetes management ...

A team of researchers from Sweden, the U.S. and Switzerland has found that treating rat liver cells with a compound called sulforaphane, which is found in cruciferous vegetables, reduced production of glucose. In their paper ...

(HealthDay)For many people with diabetes, low blood sugar levels are a serious health risk, but researchers report that a new nasal powder quickly reverses the effects of this dangerous condition.

An inexpensive first-line treatment for type 2 diabetes may also reduce heart disease in those with type 1 diabetes, according to a new global trial led by the University of Glasgow.

In a landmark study, UNC School of Medicine researchers have shown that blood glucose testing does not offer a significant advantage in blood sugar control or quality of life for type 2 diabetes patients who are not treated ...

Low-income Hispanics with Type 2 diabetes who received health-related text messages every day for six months saw improvements in their blood sugar levels that equaled those resulting from some glucose-lowering medications, ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:
'Protective shield' for beta-cells suggests new option to treat diabetes - Medical Xpress